Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in: Discover Oncology 1/2024

Open Access 01-12-2024 | Metastasis | Review

Solid pseudopapillary neoplasm (SPN) of the pancreas: current understanding on its malignant potential and management

Authors: Xiaoyue Lu, Hao Chen, Taiping Zhang

Published in: Discover Oncology | Issue 1/2024

Login to get access

Abstract

Solid pseudopapillary neoplasms (SPN) of the pancreas are presently recognized as low-grade malignant tumors that are frequently observed in young females. This tumor has a low incidence and is associated with an excellent prognosis following surgical resection. Typical SPNs primarily affect the pancreas and tend to have moderate or asymptomatic manifestations. Based on retrospective research, it is anticipated that patients with SPN can achieve disease-free survival, even in cases when metastasis is detected during inspection. However, the incidence of malignant SPN has been consistently underestimated, as evidenced by recent research findings. Malignancy of SPN primarily encompasses invasion and infiltration, metastasis, and recurrence after R0 resection. Imaging technologies such as Ultrasound, Computed Tomography, Magnetic Resonance Imaging, and Position Emission Tomography are capable of preliminarily identifying malignant SPN, which is primarily based on its invasive clinical features. Research on risk factors of malignant SPN revealed that larger tumor size, Ki-67 index, and several other parameters had significant correlations with invasive tumor behavior. Pathologic features of malignant SPNs overlay other pancreatic tumors, nevertheless they can provide valuable assistance in the process of diagnosis. Several confirmed specific pathologic biomarkers are related to its cellular origin, characteristic gene mutation, and cell proliferation. Considering the invasiveness of malignant SPN, it is imperative to enhance the comprehensiveness of its therapy. Tumor resection remains a suggested course of action in line with typical SPN, and additional lymph node dissection is seen as reasonable. Compared to benign SPNs, malignant SPNs have worse prognosis, underscoring the necessity of early identification and treatment in comprehensive medical centers to get improved clinical outcomes.
Literature
1.
Frantz VK. Tumors of the pancreas. Washington: Armed Forces Institute of Pathology; 1959.
2.
Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system. Geneva: World Health Organization; 2010.
3.
Papavramidis T, Papavramidis S. Solid pseudopapillary tumors of the pancreas: review of 718 patients reported in english literature. J Am Coll Surg. 2005;200(6):965–72.PubMedCrossRef
4.
5.
Wang P, Wei J, Wu J, et al. Diagnosis and treatment of solid-pseudopapillary tumors of the pancreas: a single institution experience with 97 cases. Pancreatology. 2018;18(4):415–9.PubMedCrossRef
6.
Wu L, Zou T, Shi D, et al. Age in combination with gender is a valuable parameter in differential diagnosis of solid pseudopapillary tumors and pancreatic neuroendocrine neoplasm. BMC Endocr Disord. 2022;22(1):255.PubMedPubMedCentralCrossRef
7.
Wu J, Mao Y, Jiang Y, et al. Sex differences in solid pseudopapillary neoplasm of the pancreas: a population-based study. Cancer Med. 2020;9(16):6030–41.PubMedPubMedCentralCrossRef
8.
A-Cienfuegos J, Lozano M, Rotellar F, et al. Solid pseudopapillary tumor of the pancreas (SPPT). Still an unsolved enigma. Rev Esp Enferm Dig. 2010;102(12):722–8.CrossRef
9.
Yang F, Yu X, Bao Y, et al. Prognostic value of Ki-67 in solid pseudopapillary tumor of the pancreas: Huashan experience and systematic review of the literature. Surgery. 2016;159(4):1023–31.PubMedCrossRef
10.
Hruban R, Pitman M, Klimstra D. Solid-pseudopapillary neoplasms. In: Silverberg SG, editor. Tumors of the pancreas. Washington DC: ARP press; 2007. p. 231–50.CrossRef
11.
Mylonas KS, Doulamis IP, Tsilimigras DI, et al. Solid pseudopapillary and malignant pancreatic tumors in childhood: a systematic review and evidence quality assessment. Pediatr Blood Cancer. 2018;65(10): e27114.PubMedCrossRef
12.
Leraas HJ, Kim J, Sun Z, et al. Solid pseudopapillary neoplasm of the pancreas in children and adults: a national study of 369 patients. J Pediatr Hematol Oncol. 2018;40(4):e233–6.PubMedCrossRef
13.
14.
Estrella JS, Li L, Rashid A, et al. Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival analyses of 64 cases from a single institution. Am J Surg Pathol. 2014;38(2):147–57.PubMedCrossRef
15.
Liu Q, Dai M, Guo J, et al. Long-term survival, quality of life, and molecular features of the patients with solid pseudopapillary neoplasm of the pancreas: a retrospective study of 454 cases. Ann Surg. 2023;278(6):1009–17.PubMedCrossRef
16.
Tang LH, Aydin H, Brennan MF, et al. Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. Am J Surg Pathol. 2005;29(4):512–9.PubMedCrossRef
17.
Chen J, Zong L, Wang P, et al. Solid pseudopapillary neoplasms of the pancreas: clinicopathologic analysis and a predictive model. Mod Pathol. 2023;36(6): 100141.PubMedCrossRef
18.
Hamilton SR, Aaltonen LA. Pathology and genetics of tumours of the digestive system. Lyon: IARC press; 2000.
19.
Song H, Dong M, Zhou J, et al. Solid pseudopapillary neoplasm of the pancreas: clinicopathologic feature, risk factors of malignancy, and survival analysis of 53 cases from a single center. Biomed Res Int. 2017;2017:5465261.PubMedPubMedCentralCrossRef
20.
Martin RCG, Klimstra DS, Brennan MF, et al. Solid-pseudopapillary tumor of the pancreas: a surgical enigma? Ann Surg Oncol. 2002;9(1):35–40.PubMedCrossRef
21.
Hao EIU, Hwang HK, Yoon DS, et al. Aggressiveness of solid pseudopapillary neoplasm of the pancreas: a literature review and meta-analysis. Medicine. 2018;97(49): e13147.PubMedPubMedCentralCrossRef
22.
Reindl BA, Lynch DW, Jassim AD. Aggressive variant of a solid pseudopapillary neoplasm: a case report and literature review. Arch Pathol Lab Med. 2014;138(7):974–8.PubMedCrossRef
23.
24.
25.
Chauhan U, Puri SK, Jain N, et al. Percutaneous thrombin injection under sonographic guidance for exclusion of non-catheterizable post-pancreatitis pseudoaneurysm of the superior mesenteric artery: a minimally invasive and expeditious treatment option. J Med Ultrason. 2016;43(2):295–9.CrossRef
26.
Li Z, Pan D, Wang M, et al. Application of MSCT characteristic nomogram model in predicting invasion of pancreatic solid pseudopapillary neoplasms. Eur J Radiol. 2022;149: 110201.PubMedCrossRef
27.
Anil G, Zhang J, Al Hamar NE, et al. Solid pseudopapillary neoplasm of the pancreas: CT imaging features and radiologic-pathologic correlation. Diagn Interv Radiol. 2017;23(2):94–9.PubMedPubMedCentralCrossRef
28.
Huang WP, Liu SY, Han YJ, et al. Development of CT-based imaging signature for preoperative prediction of invasive behavior in pancreatic solid pseudopapillary neoplasm. Front Oncol. 2021;11: 677814.PubMedPubMedCentralCrossRef
29.
Sharma P, Hegde R, Kulkarni A, et al. Imaging right lower quadrant pain: not always appendicitis. Clin Imaging. 2020;63:65–82.PubMedCrossRef
30.
Gandhi D, Garg G, Solanki S, et al. Deep infiltrating endometriosis: role of magnetic resonance subtraction imaging. Quant Imaging Med Surg. 2018;8(8):722–3.PubMedPubMedCentralCrossRef
31.
He C, Zhu L, Wang X, et al. Presumed radiological diagnosis of solid pseudopapillary tumors: do we really know what we are watching? Pancreatology. 2023;23(1):120–8.PubMedCrossRef
32.
Wu J, Lin Y, Wu J. Intraductal papillary mucinous neoplasm complicated with intraductal bleeding in a young woman mimicked a cystic solid pseudo-papillary tumor: a case report. BMC Gastroenterol. 2020;20(1):1.CrossRef
33.
Kang CM, Cho A, Kim H, et al. Clinical correlations with 18FDG PET scan patterns in solid pseudopapillary tumors of the pancreas: still a surgical enigma? Pancreatology. 2014;14(6):515–23.PubMedCrossRef
34.
Sato M, Takasaka I, Okumura T, et al. High F-18 fluorodeoxyglucose accumulation in solid pseudo-papillary tumors of the pancreas. Ann Nucl Med. 2006;20:431–6.PubMedCrossRef
35.
Sopjani M, Alesutan I, Wilmes J, et al. Stimulation of Na+/K+ ATPase activity and Na+ coupled glucose transport by β-catenin. Biochem Biophys Res Commun. 2010;402(3):467–70.PubMedCrossRef
36.
Dehner M, Hadjihannas M, Weiske J, et al. Wnt signaling inhibits Forkhead box O3a-induced transcription and apoptosis through up-regulation of serum-and glucocorticoid-inducible kinase 1. J Biol Chem. 2008;283(28):19201–10.PubMedCrossRef
37.
Naishiro Y, Yamada T, Idogawa M, et al. Morphological and transcriptional responses of untransformed intestinal epithelial cells to an oncogenic β-catenin protein. Oncogene. 2005;24(19):3141–53.PubMedCrossRef
38.
Kim YI, Kim SK, Paeng JC, et al. Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma. Eur J Radiol. 2014;83(1):231–5.PubMedCrossRef
39.
Liu W, Gong W, Zhang J, et al. 68Ga-FAPI-04 PET/CT in the detection of Non–FDG-Avid solid pseudopapillary neoplasm of the pancreas. Clin Nucl Med. 2023;48(1):100–2.PubMedCrossRef
40.
Cavaliere A, Giraudo C, Zuliani M, et al. 18F-FDG PET/MR in an atypical pediatric solid pseudopapillary pancreatic tumor. Clin Nucl Med. 2019;44(9):e522–3.PubMedCrossRef
41.
Zhou J, Xie J, Pan Y, et al. Detection of adult pancreatoblastoma by 18F-FDG and 68Ga-DOTATATE PET/MR. Clin Nucl Med. 2021;46(8):671–4.PubMedCrossRef
42.
Chen H, Huang Y, Yang N, et al. Solid-pseudopapillary neoplasm of the pancreas: a 63-case analysis of clinicopathologic and immunohistochemical features and risk factors of malignancy. Cancer Manag Res. 2021;13:3335–43.PubMedPubMedCentralCrossRef
43.
Yang F, Wu W, Wang X, et al. Grading solid pseudopapillary tumors of the pancreas: the Fudan prognostic index. Ann Surg Oncol. 2021;28(1):550–9.PubMedCrossRef
44.
Kang CM, Choi SH, Kim SC, et al. Predicting recurrence of pancreatic solid pseudopapillary tumors after surgical resection: a multicenter analysis in Korea. Ann Surg. 2014;260(2):348–55.PubMedCrossRef
45.
Lee G, Sung YN, Kim SJ, et al. Large tumor size, lymphovascular invasion, and synchronous metastasis are associated with the recurrence of solid pseudopapillary neoplasms of the pancreas. HPB. 2021;23(2):220–30.PubMedCrossRef
46.
Yang J, Tan CL, Long D, et al. Analysis of invasiveness and tumor-associated macrophages infiltration in solid pseudopapillary tumors of pancreas. World J Gastroenterol. 2022;28(34):5047.PubMedPubMedCentralCrossRef
47.
Paredes O, Paredes K, Kawaguchi Y, et al. Clinicopathological factors associated with recurrence in patients undergoing resection of pancreatic solid pseudopapillary neoplasm. Discov Oncol. 2021;12(1):1.
48.
49.
50.
Wang Q, Reid MD. Cytopathology of solid pancreatic neoplasms: an algorithmic approach to diagnosis. Cancer Cytopathol. 2022;130(7):491–510.PubMedCrossRef
51.
Deshpande V, Mino-Kenudson M, Brugge WR, et al. Endoscopic ultrasound guided fine needle aspiration biopsy of autoimmune pancreatitis: diagnostic criteria and pitfalls. Am J Surg Pathol. 2005;29(11):1464–71.PubMedCrossRef
52.
Zhang C, Liu F, Chang H, et al. Less aggressive surgical procedure for treatment of solid pseudopapillary tumor: limited experience from a single institute. PLoS ONE. 2015;10(11): e0143452.PubMedPubMedCentralCrossRef
53.
Park M, Kim M, Hwang D, et al. Characterization of gene expression and activated signaling pathways in solid-pseudopapillary neoplasm of pancreas. Mod Pathol. 2014;27(4):580–93.PubMedCrossRef
54.
la Rosa S, Bongiovanni M. Pancreatic solid pseudopapillary neoplasm: key pathologic and genetic features. Arch Pathol Lab Med. 2020;144(7):829–37.PubMedCrossRef
55.
Ghio M, Vijay A. Molecular alterations in solid pseudopapillary neoplasm of the pancreas: the Achilles Heel in conquering pancreatic tumorigenesis. Pancreas. 2021;50(10):1343–7.PubMedCrossRef
56.
Amato E, Mafficini A, Hirabayashi K, et al. Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas. J Pathol. 2019;247(1):123–34.PubMedCrossRef
57.
Standring O, Benitez Sanchez S, Pasha S, et al. Potential role for observation in small solid pseudopapillary neoplasm (SPN). Ann Surg Oncol. 2023;30(8):5105–12.PubMedCrossRef
58.
Wei G, Luo Q, Fang J, et al. The sex features of patients with solid pseudopapillary neoplasms of the pancreas: a retrospective study. Front Oncol. 2022;12: 844182.PubMedPubMedCentralCrossRef
59.
Calvani J, Lopez P, Sarnacki S, et al. Solid pseudopapillary neoplasms of the pancreas do not express major pancreatic markers in pediatric patients. Hum Pathol. 2019;83:29–35.PubMedCrossRef
60.
Gao N, Lelay J, Vatamaniuk MZ, et al. Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. Genes Dev. 2008;22(24):3435–48.PubMedPubMedCentralCrossRef
61.
Abraham SC, Klimstra DS, Wilentz RE, et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol. 2002;160(4):1361–9.PubMedPubMedCentralCrossRef
62.
Terris B, Cavard C. Diagnosis and molecular aspects of solid-pseudopapillary neoplasms of the pancreas. Semin Diagn Pathol. 2014;31(6):484–90.PubMedCrossRef
63.
Deshpande V, Oliva E, Young RH. Solid pseudopapillary neoplasm of the ovary: a report of 3 primary ovarian tumors resembling those of the pancreas. Am J Surg Pathol. 2010;34(10):1514–20.PubMedCrossRef
64.
Kushner BS, Chatterjee D, Hammill C. Rare aggressive solid pseudopapillary neoplasm of the ovary with metastatic disease following surgical resection. BMJ Case Rep. 2020;13(12): e238136.PubMedPubMedCentralCrossRef
65.
Gahlot GP, Mridha AR, Sable M, et al. Solid pseudopapillary neoplasm of the ovary with metastases to the omentum and regional lymph nodes. Indian J Pathol Microbiol. 2016;59(3):348–50.PubMedCrossRef
66.
Kurokawa S, Hirabayashi K, Hadano A, et al. Do solid pseudopapillary neoplasms shrink after menopause?: Review of the literature. Pancreas. 2015;44(6):998–9.PubMedCrossRef
67.
Geers C, Moulin P, Gigot JF, et al. Solid and pseudopapillary tumor of the pancreas—review and new insights into pathogenesis. Am J Surg Pathol. 2006;30(10):1243–9.PubMedCrossRef
68.
Matos JM, Grützmann R, Agaram NP, et al. Solid pseudopapillary neoplasms of the pancreas: a multi-institutional study of 21 patients. J Surg Res. 2009;157(1):e137–42.PubMedCrossRef
69.
Vassos N, Agaimy A, Klein P, et al. Solid-pseudopapillary neoplasm (SPN) of the pancreas: case series and literature review on an enigmatic entity. Int J Clin Exp Pathol. 2013;6(6):1051–9.PubMedPubMedCentral
70.
Tanaka Y, Kato K, Notohara K, et al. Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. Can Res. 2001;61(23):8401–4.
71.
de Man SMA, van Amerongen R. Zooming in on the WNT/CTNNB1 destruction complex: functional mechanistic details with implications for therapeutic targeting. Handb Exp Pharmacol. 2021;269:137–73.PubMedCrossRef
72.
73.
Mohammed MK, Shao C, Wang J, et al. Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. Genes Dis. 2016;3(1):11–40.PubMedPubMedCentralCrossRef
74.
Basu S, Cheriyamundath S, Ben-Ze’ev A. Cell-cell adhesion: linking Wnt/β-catenin signaling with partial EMT and stemness traits in tumorigenesis. F1000 Res. 2018;7:1488.CrossRef
75.
Tang WW, Stelter AA, French S, et al. Loss of cell-adhesion molecule complexes in solid pseudopapillary tumor of pancreas. Mod Pathol. 2007;20(5):509–13.PubMedCrossRef
76.
van der Wal T, van Amerongen R. Walking the tight wire between cell adhesion and WNT signalling: a balancing act for β-catenin. Open Biol. 2020;10(12): 200267.PubMedPubMedCentralCrossRef
77.
Tiemann K, Heitling U, Kosmahl M, et al. Solid pseudopapillary neoplasms of the pancreas show an interruption of the Wnt-signaling pathway and express gene products of 11q. Mod Pathol. 2007;20(9):955–60.PubMedCrossRef
78.
79.
Kim EK, Jang M, Park M, et al. LEF1, TFE3, and AR are putative diagnostic markers of solid pseudopapillary neoplasms. Oncotarget. 2017;8(55):93404–13.PubMedPubMedCentralCrossRef
80.
Yu P, Cheng X, Du Y, et al. Solid pseudopapillary neoplasms of the pancreas: a 19-year multicenter experience in China. J Gastrointest Surg. 2015;19(8):1433–40.PubMedCrossRef
81.
82.
Ohara Y, Oda T, Hashimoto S, et al. Pancreatic neuroendocrine tumor and solid-pseudopapillary neoplasm: key immunohistochemical profiles for differential diagnosis. World J Gastroenterol. 2016;22(38):8596–604.PubMedPubMedCentralCrossRef
83.
European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67(5):789–804.CrossRef
84.
Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Gastroenterology. 2014;146(1):291-304 e1.PubMedCrossRef
85.
Wang X, Chen YH, Tan CL, et al. Enucleation of pancreatic solid pseudopapillary neoplasm: short-term and long-term outcomes from a 7-year large single-center experience. Eur J Surg Oncol. 2018;44(5):644–50.PubMedCrossRef
86.
Cho YJ, Namgoong JM, Kim DY, et al. Suggested indications for enucleation of solid pseudopapillary neoplasms in pediatric patients. Front Pediatr. 2019;7:125.PubMedPubMedCentralCrossRef
87.
Gao Y, Guo F, Lu Z, et al. Perioperative safety and prognosis following parenchyma-preserving surgery for solid pseudopapillary neoplasm of the pancreas. World J Surg Oncol. 2023;21(1):119.PubMedPubMedCentralCrossRef
88.
89.
Butte JM, Brennan MF, Gönen M, et al. Solid pseudopapillary tumors of the pancreas clinical features, surgical outcomes, and long-term survival in 45 consecutive patients from a single center. J Gastroint Surg. 2011;15(2):350–7.CrossRef
90.
Okubo Y, Yamamoto Y, Sato S, et al. Diagnostic significance of reassessment of prostate biopsy specimens by experienced urological pathologists at a high-volume institution. Virchows Arch. 2022;480(5):979–87.PubMedPubMedCentralCrossRef
91.
Kang CM, Kim H, Cho Y, et al. In vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) in solid pseudopapillary tumor of the pancreas. Pancreas. 2012;41(3):498–500.PubMedCrossRef
92.
Shang Y, Zhang Y, Pan E, et al. A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: a case report. Front Oncol. 2022;12:1022290.PubMedPubMedCentralCrossRef
93.
Kim JS, Hao EI, Rho SY, et al. Clinical pattern of preoperative positron emission tomography/computed tomography (PET/CT) can predict the aggressive behavior of resected solid pseudopapillary neoplasm of the pancreas. Cancers (Basel). 2021;13(9):2119.PubMedCrossRef
94.
Li X, Liu Y. Spontaneous regression of solid-pseudopapillary neoplasms with hepatic metastases. Hepatobiliary Surgery and Nutrition. 2022;11(1):169–70.PubMedPubMedCentralCrossRef
Metadata
Title
Solid pseudopapillary neoplasm (SPN) of the pancreas: current understanding on its malignant potential and management
Authors
Xiaoyue Lu
Hao Chen
Taiping Zhang
Publication date
01-12-2024
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-024-00905-5

Other articles of this Issue 1/2024

Discover Oncology 1/2024 Go to the issue

Research

L-cysteine contributes to destructive activities of odontogenic cysts/tumor

Case Report

A rare case report: multiple intrahepatic masses in a pediatric patient with citrin deficiency

Research

Integrative analysis indicates the potential values of ANKRD53 in stomach adenocarcinoma

Review

Research progress of exosomes in the angiogenesis of digestive system tumour

Analysis

Comprehensive analysis and prognostic assessment of senescence-associated genes in bladder cancer

Research

Semi-supervised skin cancer diagnosis based on self-feedback threshold focal learning
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits